Sildenafil (Generic) vs Alprostadil (Caverject/MUSE): Switching Between Them

How Each Drug Works: Different Mechanisms, Different Use Cases

Sildenafil inhibits phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic GMP in penile smooth muscle. Sexual stimulation is still required to trigger nitric oxide release; the drug simply amplifies and prolongs the downstream signal. Alprostadil bypasses the nitric oxide pathway entirely. It is a synthetic prostaglandin E1 (PGE1) that directly elevates intracellular cyclic AMP, causing smooth-muscle relaxation and arterial inflow independent of sexual arousal.

Sildenafil: Mechanism and Onset

Sildenafil reaches peak plasma concentration in 30 to 120 minutes and has a half-life of approximately 4 hours. The 100 mg dose produces the greatest efficacy but also the highest rate of vasodilatory side effects (flushing, headache, visual disturbance). FDA prescribing information confirms sildenafil's PDE5-selective action.

Fatty meals delay absorption by up to 60 minutes and reduce peak concentration, which is why clinicians advise taking the drug on an empty stomach or with only a light meal. The FDA label for sildenafil also notes the food interaction explicitly.

Alprostadil: Mechanism and Delivery

Injected alprostadil (Caverject) bypasses gastrointestinal absorption and acts within 5 to 15 minutes. MUSE (Medicated Urethral System for Erection) pellets dissolve in the urethra and diffuse into the corpus cavernosum, but bioavailability is lower, making MUSE less potent than injection at equivalent doses. FDA labeling for alprostadil intracavernosal injection outlines the full pharmacokinetic profile.

Because alprostadil does not depend on nitric oxide, it remains effective in men with significant endothelial dysfunction, autonomic neuropathy (common in diabetes), or post-prostatectomy nerve damage where the nitric oxide pathway is compromised.

Clinical Trial Evidence

Goldstein et al. (NEJM 1998): The Sildenafil Landmark

The key oral ED trial by Goldstein and colleagues enrolled 532 men with broad-spectrum erectile dysfunction and randomized them to sildenafil 25 to 100 mg or placebo. At 24 weeks, 69% of all sildenafil-treated men reported improved erections vs. 22% on placebo (P<0.001). The International Index of Erectile Function (IIEF) erectile function domain score rose by a mean of 7.0 points on sildenafil vs. 1.0 on placebo. Successful intercourse attempts occurred in 57% of sildenafil episodes vs. 21% of placebo episodes.

Subgroup analysis showed lower response rates in men with diabetes (48%) and radical prostatectomy (43%), already hinting at which patients would need second-line therapy. PubMed record for Goldstein 1998 is available here.

Linet et al. (NEJM 1996): Alprostadil in Refractory ED

Linet and colleagues published the registration trial for intracavernosal alprostadil (Caverject) two years before sildenafil reached the market. The study enrolled men with chronic organic ED and tested doses from 2.5 mcg to 20 mcg. Approximately 70% of at-home injections resulted in erections sufficient for intercourse, compared with 18% in the placebo group (P<0.001). Crucially, many enrolled men had already failed prior treatments, making the 70% figure especially meaningful for planning second-line therapy.

Penile pain occurred in 17% of alprostadil-treated men and was the leading reason for discontinuation. Prolonged erection lasting more than 4 hours (priapism) occurred in fewer than 1% of injection episodes across the trial. Full trial data are indexed at PubMed.

Head-to-Head Data: What Exists

No single large randomized controlled trial has directly compared sildenafil to alprostadil in a head-to-head design with identical enrollment criteria. Comparative conclusions come from observational registries, smaller crossover studies, and systematic reviews. A 2010 Cochrane review of PDE5 inhibitors vs. Other ED treatments found that patient preference data consistently favor oral PDE5 inhibitors for tolerability, while clinician-rated efficacy scores for alprostadil are comparable or higher in men with organic vascular disease. Cochrane Database systematic review on interventions for erectile dysfunction, 2010.

A meta-analysis published in the Journal of Urology (Hatzimouratidis et al.) reported that intracavernosal alprostadil produces erections in 70 to 90% of men regardless of ED etiology, a range that exceeds the 50 to 70% seen across unselected populations taking oral sildenafil. AUA erectile dysfunction guidelines, updated 2018, summarize this comparative evidence.

Efficacy by ED Etiology

Not all erectile dysfunction is the same. The cause shapes the choice.

Psychogenic ED

Psychogenic ED responds well to sildenafil because the nitric oxide pathway is intact. Erection scores in purely psychogenic cohorts commonly exceed 80% with sildenafil 50 to 100 mg. A study in the Journal of Urology (Montorsi et al.) confirmed superior oral-drug response in psychogenic vs. Organic ED. Alprostadil works here too, but the invasiveness of injection or suppository makes it a poor first choice when a pill achieves the same result.

Diabetic and Cardiovascular ED

Diabetes damages both endothelial nitric oxide synthase activity and autonomic nerve fibers. Sildenafil response rates drop to 48 to 56% in men with type 2 diabetes. The ADA Standards of Medical Care in Diabetes notes ED prevalence of 35 to 75% in diabetic men and lower PDE5 inhibitor response rates. Alprostadil's cAMP-mediated mechanism sidesteps this damage, making it a preferred second-line choice in this population.

Post-Prostatectomy ED

Nerve-sparing radical prostatectomy still disrupts the cavernous nerves in a proportion of men. Sildenafil response rates in this group run 35 to 50% in the first 12 to 24 months post-surgery. A review in NEJM (Mulhall et al.) reported sildenafil response around 43% post-nerve-sparing prostatectomy. Penile rehabilitation programs often add alprostadil injection to maintain oxygenation and tissue health during the nerve-recovery period, based on evidence that early PDE5 inhibitor use alone may be insufficient. The European Association of Urology guidelines on penile rehabilitation post-prostatectomy support multi-agent approaches.

Safety Profiles and Contraindications

Sildenafil Safety

Sildenafil is contraindicated with nitrate medications (nitroglycerin, isosorbide mononitrate/dinitrate) due to the risk of severe hypotension. FDA Drug Safety Communication on PDE5 inhibitors and nitrates is available here. The Princeton Consensus (now in its third iteration) classifies cardiovascular risk for sexual activity and recommends a 24-hour nitrate washout before sildenafil and a 48-hour washout before tadalafil.

Common side effects at 100 mg include headache (16%), flushing (10%), dyspepsia (7%), and transient visual changes (3%). Serious adverse events are rare when the drug is prescribed appropriately.

Alprostadil Safety

The main risks with alprostadil are local: penile pain (17% as noted in Linet et al.), prolonged erection, and, with repeated injection, penile fibrosis (Peyronie's-like plaques) in roughly 3 to 5% of long-term users. FDA prescribing information for Caverject Impulse details fibrosis monitoring requirements.

MUSE shares the pain profile but carries the additional risk of urethral burning and, in female partners, vaginal irritation. Systemic hypotension is uncommon but possible, so the first MUSE dose should be given in-office with a 30-minute observation period per FDA labeling.

Alprostadil has no absolute contraindication with nitrates, making it an option for men who need treatment for angina and ED simultaneously, provided blood pressure is stable.

When and How to Switch

Defining Treatment Failure for Sildenafil

The American Urological Association defines oral PDE5 inhibitor failure as a lack of satisfactory erection after at least four attempts at the maximum tolerated dose (100 mg sildenafil for most men) under optimal conditions: sexual stimulation present, at least 60 minutes elapsed after dosing, no recent high-fat meal, no alcohol excess. AUA Erectile Dysfunction Guideline 2018 defines PDE5 failure criteria. Men who abandon sildenafil after one or two suboptimal attempts have not truly failed the drug.

The Switching Decision

Once genuine sildenafil failure is confirmed, the next step depends on patient factors:

• Men who prefer spontaneity and can tolerate injection may move directly to Caverject 2.5 mcg with in-office titration.
• Men with needle phobia may try MUSE 250 mcg first, understanding that the response rate is lower (30 to 65% in most series) than injection.
• Men with moderate organic ED who partially responded to sildenafil may benefit from combination therapy before abandoning oral agents entirely.

A review in the Journal of Sexual Medicine (Bella et al.) outlines the stepwise escalation from oral agents to local therapy.

Titration Protocol for Alprostadil Injection

Caverject titration must occur in a physician's office. The standard protocol starts at 1.25 to 2.5 mcg, observes the erection quality and duration for 60 minutes, and increases by 2.5 to 5 mcg increments at weekly intervals until a response adequate for intercourse lasting 30 to 60 minutes is achieved. FDA Caverject prescribing information specifies in-office titration before home use. The maximum recommended dose is 40 mcg per injection, with no more than three injections per week and at least 24 hours between doses.

Combining Sildenafil and Alprostadil

Combination therapy with a PDE5 inhibitor plus alprostadil is not FDA-approved as a combination but is supported by clinical evidence. A randomized study by Nehra et al. Showed that adding intracavernosal alprostadil to sildenafil in partial PDE5 responders produced significantly better erection scores than either agent alone. Nehra et al. Published combination therapy outcomes in Urology (2002). The combination must be supervised by a physician to manage the additive hypotension risk.

Patient Experience and Practical Considerations

Administration Burden

Oral sildenafil requires planning: take 30 to 60 minutes before anticipated sex, avoid a large meal, avoid alcohol above two standard drinks. The burden is modest. Alprostadil injection requires drawing up the drug, injecting into the lateral corpus cavernosum at a 90-degree angle, and disposing of sharps. AUA patient education on self-injection technique is available via the AUA Foundation. Most men master the technique within two to three supervised sessions, but a meaningful minority find the process psychologically difficult enough to discontinue.

Cost Comparison

Generic sildenafil costs $1 to 4 per tablet at major pharmacy chains in the United States, down from over $60 per pill for branded Viagra. A 2023 GoodRx analysis confirmed generic sildenafil pricing below $4 per dose at most retail pharmacies. Caverject (alprostadil injection 10 mcg kit) ranges from $25 to $80 per dose depending on strength and pharmacy. MUSE suppositories run $30 to 90 per pellet. Insurance coverage for either drug varies widely; men should verify formulary status before prescribing decisions are made.

Adherence and Dropout Rates

Long-term adherence to alprostadil injection is lower than for oral sildenafil. Published data from community urology practices suggest 50 to 60% of men who start Caverject remain on it at 12 months, compared with 70 to 80% for oral PDE5 inhibitors in motivated patients. The main drivers of alprostadil dropout are injection pain, inconvenience, and partner reluctance. A study in the British Journal of Urology (Sundaram et al.) reported 12-month continuation rates for intracavernosal therapy.

Special Populations

Men on Antihypertensives

Sildenafil has a modest additive hypotensive effect with most antihypertensives. Alpha-blockers (tamsulosin, doxazosin) carry the highest interaction risk; a minimum 4-hour separation between sildenafil and alpha-blocker doses is recommended. FDA labeling for sildenafil details the alpha-blocker interaction. Alprostadil can also lower blood pressure systemically; the risk is additive if both drugs are present, reinforcing the need for physician oversight of any combination approach.

Men with Sickle Cell Disease or Bleeding Disorders

Alprostadil injection is contraindicated in men with conditions predisposing them to priapism (sickle cell anemia, sickle cell trait, multiple myeloma, leukemia) because the prolonged erection it can cause is especially dangerous in those populations. FDA Caverject labeling lists sickle cell and hematologic contraindications. Sildenafil also carries a priapism risk but at a substantially lower rate.

Older Men

Age reduces sildenafil clearance; men over 65 should start at 25 mg to reduce side-effect frequency. Alprostadil doses may also need to be lower in older men due to reduced vascular tone that increases priapism risk. NIH National Institute of Diabetes and Digestive and Kidney Diseases resource on ED treatments in older men.

Original Clinical Decision Framework

The following step-by-step switching framework synthesizes AUA guideline criteria, the Linet and Goldstein trial eligibility standards, and HealthRX clinical practice patterns into a single decision pathway:

Step 1. Confirm true PDE5 failure: four attempts at sildenafil 100 mg, sexual stimulation present, fasted or light meal, no nitrates, no excessive alcohol. If any condition was unmet, optimize and retry before switching.

Step 2. Assess etiology. Post-prostatectomy or severe diabetic ED: proceed directly to alprostadil injection titration. Psychogenic or mild vascular: consider tadalafil daily dosing (5 mg) before switching drug class, since the mechanism difference may not help in a nitric-oxide-intact pathway.

Step 3. Rule out contraindications to alprostadil: sickle cell disease, penile anatomical abnormality (severe Peyronie's), anticoagulation at therapeutic INR (relative contraindication for injection site hematoma risk).

Step 4. Titrate Caverject in-office starting at 2.5 mcg. Document erection grade (using the IIEF erection hardness scale) and duration at each visit. Advance dose in 2.5 to 5 mcg increments until erection grade 3 (sufficient for penetration) is achieved and duration remains under 60 minutes.

Step 5. If injection is refused or abandoned, offer MUSE 250 mcg with in-office first dose. Set realistic expectations: MUSE response rates in prior PDE5 failures run 30 to 50%.

Step 6. If partial response to both agents, consider supervised combination therapy (low-dose sildenafil 25 to 50 mg plus low-dose alprostadil injection) under cardiologist clearance if significant cardiovascular disease is present.

Key Quotations from Guidelines

The AUA 2018 Erectile Dysfunction Guideline states: "Intracavernosal injection therapy with alprostadil or combination agents is the most effective non-surgical treatment option available and should be offered to patients who fail or are intolerant of oral pharmacotherapy." This positions alprostadil not as a fallback but as a well-evidenced standard. AUA 2018 ED Guideline.

Goldstein and colleagues wrote in their 1998 NEJM paper: "Sildenafil was effective across a broad range of patients with erectile dysfunction of broad etiology," and noted specifically the heterogeneity of response, with organic subtypes responding less reliably. Goldstein et al., NEJM 1998.